InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,424.40
(
0.11%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.79
(
1.05%
)
Bitcoin
65,231.55
(
-1.89%
)
Post# of 252249
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119871
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 153025

Tuesday, 11/27/2012 7:24:04 PM

Tuesday, November 27, 2012 7:24:04 PM

Post# of 252249
Re: GILD POSITRON GT2 vs GT3

Although not explicitly disclosed in GILD’s POSITRON PR (#msg-81844469), by elementary algebra we can solve for the number of patients in the trial with GT2 and GT3, respectively.

GT2 SVR12 rate was 93% (101/109)
GT3 SVR12 rate was 61% (60/98)
---
Overall SVR12 rate was 78% (161/207)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up